The Treatment Satisfaction Scale: A Multidimensional Instrument for the Assessment of Treatment Satisfaction for Erectile Dysfunction Patients and Their Partners

DiBenedetti, Dana; Gondek, Kathleen; Sagnier, Pierre-Philippe; Kubin, Maria; Marquis, Patrick; Keininger, Dorothy L.; Fugl‐Meyer, Axel R.

doi:10.1016/j.eururo.2005.05.008

Cited by 39 publications

(36 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar floor/ceiling effects are seen in widely used scale such as the SF 36 [30–32] and in other satisfaction scales [33]. The instrument should take approximately 2 minutes to complete.…”

Section: Discussionmentioning

confidence: 71%

The Self-Administered Patient Satisfaction Scale for Primary Hip and Knee Arthroplasty

et al. 2011

View full text Add to dashboard Cite

Introduction. The objective of this study was to develop a short self-report questionnaire for evaluating patient satisfaction with the outcome of hip and knee replacement surgery. Methods. This scale consists of four items focusing on satisfaction with the extent of pain relief, improvement in ability to perform home or yard work, ability to perform recreational activities, and overall satisfaction with joint replacement. This instrument does not measure satisfaction with process of care. The responses are scored on a Likert scale, with the total score ranging from 25 to 100 per question. The instrument was tested on 1700 patients undergoing primary total hip and total knee replacement surgery, evaluated preoperatively, at 12 weeks, and one year postoperatively. Psychometric testing included internal consistency, measured with Cronbach's alpha, and convergent validity, measured by correlation with changes in measures of health status between the preoperative, 12-week, and one-year evaluations. Results. The internal consistency (reliability) of the scale, measured by the Cronbach's alpha, ranged from 0.86 to 0.92. The scale demonstrated substantial ceiling effects at 1 year. The scale scores correlated modestly with the absolute SF-36 PCS and WOMAC scores (ρ = 0.56–0.63 and also with the WOMAC change scores (ρ = 0.38–0.46) at both 12-week and 1-year followups. Conclusions. This instrument is valid and reliable for measuring patient satisfaction following primary hip and knee arthroplasty and could be further evaluated for use with other musculoskeletal interventions.

show abstract

Section: Discussionmentioning

confidence: 71%

The Self-Administered Patient Satisfaction Scale for Primary Hip and Knee Arthroplasty

et al. 2011

View full text Add to dashboard Cite

show abstract

“…It rates the couples’ satisfaction with treatment and includes a baseline measure, which allows any changes before and after treatment to be monitored. The TSS consists of four modules: unmedicated patient, medicated patient, unmedicated partner, and medicated partner [15,16], and each module contains the domains “ease with erection,”“erectile function satisfaction,”“pleasure from sexual activity,”“satisfaction with orgasms,” and “confidence to complete sexual activity.” An additional domain, “satisfaction with medication,” is only assessed after treatment in the medicated modules. The TSS has been validated, and the questionnaire has been proven to be culturally, linguistically, and psychometrically sound [16].…”

Section: Methodsmentioning

confidence: 99%

Vardenafil Improves Sexual Function and Treatment Satisfaction in Couples Affected by Erectile Dysfunction (ED): A Randomized, Double-Blind, Placebo-Controlled Trial in PDE5 Inhibitor-Naïve Men with ED and Their Partners

Edwards

Hackett

Collins

et al. 2006

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction Erectile dysfunction (ED) is a common condition with diverse sequelae affecting men and their women partners. Aim The FINDER study aimed to evaluate the efficacy and tolerability of the phosphodiesterase type-5 (PDE5) inhibitor, vardenafil, in a broad population of PDE5-naïve men with ED of different etiologies and severity and included their partners’ assessments of treatment with vardenafil. Methods Men with ED (N = 260) were randomized to receive either vardenafil or placebo in a multicenter, flexible-dose study. Main Outcome Measures Primary efficacy variables were patients’ responses to the Global Assessment Question (GAQ), and Sexual Encounter Profile questions 2 and 3 (SEP2 and SEP3). Results Compared with placebo, vardenafil significantly improved rates of successful “Yes” responses to SEP3 (“Did your erection last long enough for you to have successful intercourse?”) (49% placebo vs. 78% vardenafil at last period carried forward [LPCF]; P < 0.0001), SEP2 (“Were you able to insert your penis into your partner’s vagina?”) (65% placebo vs. 85% vardenafil at LPCF; P < 0.0001), and GAQ (36% placebo vs. 83% vardenafil at last observation carried forward; P < 0.0001). In addition, patients’ and their partners’ Treatment Satisfaction Scale (TSS) scores were statistically significantly improved across each of the TSS domains (satisfaction with orgasm, ease with erection, confidence, pleasure, erectile function satisfaction, and satisfaction with medication) in the vardenafil group compared with the placebo group. Conclusions Vardenafil improved sexual function to the extent that both patients and their partners expressed a considerable and agreed level of satisfaction with treatment.

show abstract

“…Dimensions of sexual pleasure and confidence were not assessed by EDITS. 36 Although the sample size was small (n ¼ 111), the power was 40.8, because only the pairedsamples t-test and w 2 test were used. Female sexual function, which may influence treatment satisfaction, was not assessed in this study.…”

Section: Pde5 Inhibitors For Erectile Dysfunction S-t Huang and B-p Jmentioning

confidence: 99%

Assessing satisfaction in men and their female partners after treatment with phosphodiesterase type 5 inhibitors for erectile dysfunction

Jiann

2013

Int J Impot Res

View full text Add to dashboard Cite

The Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) and its partner version questionnaire were used to assess couples' satisfaction with the use of phosphodiesterase type 5 (PDE5) inhibitors to treat erectile dysfunction (ED) over a 3-month period. Of 161 ED patients, who together with their female partners were invited to answer separate questionnaires at home, 111 patients (68.9%; mean age 61.8 (23-87) years) and female partners (mean age 52.8 (22-77) years) returned completed questionnaires. Patients reported a substantially higher treatment satisfaction score and level of satisfaction with ED treatment than their female partners (Po0.001). Patients with milder severity of ED at baseline and better erectile function after treatment were more likely to be satisfied with the outcome of the treatment. Of the different aspects of satisfaction that patients were asked about, they reported the lowest level of satisfaction about their partners' feeling about continued treatment for ED. Our study shows that more patients than their female partners are more satisfied with medical treatment for ED. To maintain long-term therapy for ED, it is important to include female partners in the assessment and management of the therapy.

show abstract

The Treatment Satisfaction Scale: A Multidimensional Instrument for the Assessment of Treatment Satisfaction for Erectile Dysfunction Patients and Their Partners

Cited by 39 publications

References 12 publications

The Self-Administered Patient Satisfaction Scale for Primary Hip and Knee Arthroplasty

The Self-Administered Patient Satisfaction Scale for Primary Hip and Knee Arthroplasty

Vardenafil Improves Sexual Function and Treatment Satisfaction in Couples Affected by Erectile Dysfunction (ED): A Randomized, Double-Blind, Placebo-Controlled Trial in PDE5 Inhibitor-Naïve Men with ED and Their Partners

Assessing satisfaction in men and their female partners after treatment with phosphodiesterase type 5 inhibitors for erectile dysfunction

Contact Info

Product

Resources

About